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ABSTRACT 
Objective: To develop two different oral formulations such as 5-fluorouracil (5-FU) tablets and oxaliplatin (OX) microspheres which were further 
filled into capsules and coated with pH-sensitive polymer (eudragit S-100) for the chronotherapeutic treatment of colon cancer (Fluorouracil: 
Oxaliplatin regimen) to perform as a substitute for intravenous (IV) route based chronomodulated chemotherapy. 
Methods: The 5-FU tablet formulation was prepared with alginate and guar gum polymers in varied concentrations using wet granulation 
technique in two varieties such as granules coated and tablet coated formulations using eudragit RSPO as coating material to achieve controlled 
drug release. Alongside OX microspheres were formulated using the ionotropic gelation methodology in combination with alginate and chitosan 
polymers in varying concentrations to accomplish a time-controlled drug release. Prepared formulations were evaluated for pre-compression and 
post-compression parameters, percentage yield, percentage drug entrapment, Fourier transformed infrared spectroscopy (FT-IR), Differential 
scanning calorimetry (DSC), Scanning electron microscopy (SEM), In vitro and Ex vivo dissolution studies. 
Results: Pre-compression and post-compression parameters for 5-FU tablets were satisfied with Indian pharmacopeia specifications. The 
entrapment efficiency of OX microspheres were increased due to the elevated concentration of polymers up to a certain level as seen in A7M, further 
greater the concentration of polymer resulted in a decline of entrapment efficiency as seen in A4M and A8M. The optimized formulations A14T and 
A14M were shown in vitro drug release of 90.36 % by 24 h and 79.63 % by 9 h respectively. 
Conclusion: The two different oral formulations of 5-FU (Tablets) and OX (Microspheres) were found to be successful in controlled drug release. 
Therefore they can be efficiently used to control the rate of drug release to the colon in synchronization with the circadian timing system in the 
belief of improved therapeutic efficacy, tolerability and overall survival rate of cancer patients. Hence it is promised to be a better alternative for 
intravenous route based chronomodulated chemotherapy. 
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regimen, Microspheres 
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INTRODUCTION 
Colon cancer is one of the three most widespread categories of 
cancers, that accounts for more than 1.5 million cases, along with 
8,62,000 deaths in the year 2018 [1, 2]. The patients in advanced 
phase of colorectal cancer require resection surgically along with 
adjuvant chemotherapy, even then patients lie at elevated menace 
for metastasis and recurrence with a 6% survival rate [3, 4]. It has 
been demonstrated that leucovorin (LV), 5-fluorouracil (5-FU) and 
oxaliplatin (OX) regimen offers better therapeutic efficacy, 
tolerability and insignificant adverse effects than 5-FU alone or 
other regimens to treat progressive colorectal cancer [5]. 
Most often these chemotherapeutic drugs are administered via the 
intravenous route, which in turn accumulates on healthy cells/tissues 
owing to non-specific dispersal of chemotherapeutic drugs [6, 7]. The 
oral route of delivering drugs is extensively adopted and the most 
readily accepted route of administration, with the dominance of being 
patient compliance, convenience, and invulnerability [8]. It also regards 
as a secure and more logical administration route for the treatment of 
colorectal conditions such as colon cancer. An ideal oral drug delivery 
system (DDS) should be able to accurately deliver the drug in a required 
manner at the preferred site without undergoing premature release and 
degradation in the GI tract. Henceforth, patients developing 
chemotherapy-related side effects can be negligible, accompanying 
enhanced bioavailability on specific target sites and reduced 
unnecessary amount of dose [9]. The pH-sensitive DDS is best suited for 
colon targeting due to different pH levels of the GI tract in various 
physiological conditions. The formulation has to be made in such a way 
that it releases drugs specifically in colonic pH [10-12]. 
Nowadays, the most burdensome challenge in the pharmaceutical 
industries for many scientists is to attune the drug release kinetics 
according to the required therapeutic range [13]. Adopting 
chronotherapy can possibly help in improving the efficacy of the 
treatment, thereby decreasing the side effects associated with 
treatment [14]. Chronopharmaceutics is a part of pharmaceutics 
committed to the design and evaluation of DDS that release 
medication at a rhythm that preferably matches the biological 
requirement of given disease therapy. Ideally, 
chronopharmaceutical DDS should consolidate site-specific and 
time-dependent DDS [15, 16]. The changes in tumor blood flow and 
cancer cell growth as per circadian rhythm are similar either tumors 
are tiny and growing expeditiously or tumors are larger and growing 
more slowly. The growth rate of tumors and the flow rate of blood 
into tumors are extensive up to three times in the course of the daily 
activity stage of the circadian cycle than during the daily rest stage 
[17, 18]. The toxicity induced by 5-FU during DNA synthesis in the 
target tissue is negligible during the night and extensive during day 
time [19]. On that account, the ratio of healthy cells possibly 
destroyed by 5-FU is lesser at night due to an increase in whole-
body clearance of 5-FU [20, 21]. The ideal chronomodulated time 
corresponding to peak delivery ranges from 12:00 am to 4:00 am for 
5-FU/lV and 1:00 pm to 6:00 pm for OX. The delivery of drug in this 
window period will help in strengthen tolerability by avoiding 
unnecessary toxicity associated with normal healthy cells, which can 
further benefit in an overall survival rate of patients compared to 
conventional chemotherapy [22, 23]. 
Thus, we are concentrating on the conversion of chronomodulated 
chemotherapy-treated through IV route into the oral route. Hereby 
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the present study aims to formulate pH-dependent, controlled 
release mini-tablets of 5-FU and OX microspheres which are further 
filled in capsules and thereafter coated with pH-sensitive polymer 
for delivering a drug into colon region at a specified concentration to 
treat colon cancer by adopting chronomodulated schedules to obtain 
patient compliance along with increased tolerability and finally to 
overcome unnecessary toxicity associated with the 5-FU and OX. 
MATERIALS AND METHODS 
Materials 
5-Fluorouracil (5-FU) was purchased from Ultra Labs (Karnataka, 
India). Oxaliplatin (OX) was obtained as a gift sample from Strides 
Arco Labs (Karnataka, India). Sodium alginate was purchased from 
Otto chemicals (Mumbai, India). Chitosan was purchased from 
Sigma-Aldrich (Bengaluru, India). Eudragit S-100, eudragit RSPO 
were purchased from Evonik. Calcium chlorides, zinc sulfate, 
polyvinylpyrrolidone k-30, acetone, acetic acid were purchased from 
SRL chemicals (Mumbai, India). 
Preparation of 5-fluorouracil tablets 
The 200 mg of 5-FU and a specified quantity of polymer sodium 
alginate were mixed thoroughly. The 10% w/v PVP K-30 in 
isopropyl alcohol was used as a binder in this preparation. The 
dough was prepared by adding an appropriate amount of binding 
solution to the previously prepared drug-polymer mixture. The 
dough mass was passed through sieve no. 16 to obtain granules and 
allowed it to dry on tray drier for 30 min at 40 °C. Finally 
compressed using 5 mm punch besides 1% w/w magnesium 
stearate as a lubricant. In the case of granule coating, the granules 
obtained after passing through sieve no. 16 were coated with the 
coating solution in a fluidized bed processor. The dried granules 
after coating were allowed to pass through sieve no. 12 and 
subsequently compressed with less than 5 mm punch using 1% w/w 
magnesium stearate as a lubricant. For tablet coating, already 
prepared 5-FU tablets were coated in a coating pan with the coating 
solution until the required amount of the eudragit RSPO gets 
uniformly coated on to the tablet. The compositions of prepared 5-
FU tablets were shown in table 1, 2. 
 
Table 1: Compositions of granule coated 5-FU formulation 
Formulation code Amount of drug in 
mg 
Amount of alginate 
in mg 
Amount of guar gum 
in mg 
% w/v of eudragit 
RSPO coating sol 
% w/v of eudragit S-
100 coating sol 
A1G 200 50 - 10 10 
A2G 200 50 - 15 10 
A3G 200 - 50 10 10 
A4G 200 - 50 15 10 
A5G 200 60 - 10 8 
A6G 200 60 - 15 8 
A7G 200 100 - 10 8 
A8G 200 100 - 15 8 
 
Table 2: Compositions of tablet coated 5-FU formulation 
Formulation code Amount of drug in 
mg 
Amount of alginate 
in mg 
Amount of guar gum 
in mg 
% w/v of eudragit 
RSPO coating sol 
% w/v of eudragit S-
100 coating sol 
A1T 200 50 - 10 10 
A2T 200 75 - 10 10 
A3T 200 - 50 10 10 
A4T 200 - 75 10 10 
A5T 200 75 - 15 10 
A6T 200 100 - 15 10 
A7T 200 50 - 15 8 
A8T 200 50 - 20 8 
A9T 200 100 - 20 8 
A10T 200 100 - 25 8 
A11T 200 40 - 20 8 
A12T 200 30 - 20 8 
A13T 200 20 - 20 8 
A14T 200 10 - 20 8 
 
Table 3: Compositions of OX microspheres 
Formulation 
code 
% w/v of 
drug 
% w/v of 
alginate 
% w/v of 
calcium ions 
% w/v of 
zinc ions 
% w/v of 
chitosan 
% w/v of eudragit S-
100 coating sol 
A1M 0.25 1.3 0.65 0.65 0.2 10 
A2M 0.25 1.3 1.3 1.3 0.2 10 
A3M 0.25 2.6 1.3 1.3 0.2 10 
A4M 0.25 3.9 1.3 1.3 0.2 10 
A5M 0.25 1.3 0.65 0.65 0.1 10 
A6M 0.25 1.3 1.3 1.3 0.1 10 
A7M 0.25 2.6 1.3 1.3 0.1 10 
A8M 0.25 3.9 1.3 1.3 0.1 10 
A9M 0.25 0.65 0.65 0.65 0.025 8 
A10M 0.25 0.33 0.33 0.33 0.013 8 
A11M 0.25 0.33 0.17 0.17 0.05 8 
A12M 0.25 0.65 0.65 - 0.025 8 
A13M 0.25 0.33 0.33 - 0.013 8 
A14M 0.25 0.33 0.17 - 0.05 8 
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Preparation of oxaliplatin microspheres 
The microspheres of OX were prepared by ionotropic gelation 
technique [24-26]. OX (0.25% w/v) was added to an aqueous 
solution of sodium alginate and stirred thoroughly for 15 min. This 
solution was dropped using a hypodermic syringe into a solution 
containing Calcium ions, Zinc ions and chitosan in acetic solution 
(0.5% v/v). Microspheres formed immediately were left for 24 h in 
the same solution to ensure internal jellification. Further filtered, 
washed and dried at room temperature [27, 28]. The detailed 
formulation components were shown in table 3. 
Preparation of coating solution 
The 10, 20, 30 and 50% w/v solution of eudragit RSPO were 
prepared in acetone using 20% w/w of di-butyl phthalate in ethanol 
for coating granules and tablets of 5-FU to achieve time-controlled 
release, further 8% and 10% w/v solution of eudragit S-100 were 
prepared in acetone using 20% w/w of di-butyl phthalate in ethanol 
for coating 5-FU tablets filled capsules and microspheres filled 
capsules. The different concentrations of eudragit RSPO coating 
solutions used to coat tablets and granules of 5-FU, further eudragit 
S-100 coating solutions used to coat capsules filled by tablets and 
microspheres were displayed in table 1, 2, 3.  
Evaluation of granule and tablet coated 5-fluorouracil tablets 
Pre-compression parameters 
Bulk density (Db) 
The bulk density of the formulated granules was evaluated using a 
bulk density apparatus. It is the ratio of total mass of powder to the 
bulk volume of powder. It was measured by pouring the weighed 
powder into a graduated measuring cylinder and the volume was 
noted [29]. It is expressed in g/ml and is given by, 
 
Where M-Mass of the powder. 
Vb-Bulk volume of the powder. 
Tapped density (Dt) 
It is the ratio of the total mass of powder to the tapped volume of 
powder. The tapped volume was measured by tapping the powder 
to a constant volume [29]. It is expressed in g/ml and is given by, 
 
Where, M-Mass of the powder.  
Vt-Tapped volume of the powder. 
Compressibility index (I) and hausner’s ratio 
Carr’s index and Hausner’s ratio measure the propensity of granule 
to be compressed and the flow ability of granule. Carr’s index and 
Hausner’s ratio were calculated using the following formula [29]. 
 
Where, Dt-Tapped density of the powder.  
Db-Bulk density of the powder. 
Hausner’s ratio 
 
Angle of repose 
The frictional forces in a loose powder can be measured by the angle 
of repose. This is the maximum angle possible between the surface 
of a pile of powder and the horizontal plane. Sufficient quantities of 
granules were passed through a funnel from a particular height (2 
cm) onto a flat surface until it formed a heap, which touched the tip 
of the funnel. The height and radius of the heap were measured. The 
angle of repose was calculated using the formula [29]. 
Angle of repose ø = tan-1(h/r) 
Where, h–Height of the pile in cm. 
r–Radius of the pile in cm. 
Post-compression parameters 
Hardness test 
The prepared 5-FU tablets were subjected to hardness test. It was 
carried out by using Labgo hardness tester type 04 and expressed in 
kg/cm2.  
Friability test (F) 
The friability was determined using Roche friabilator and expressed 
in percentage. The 20 tablets of 5-FU from each batch were weighed 
separately (W initial) and placed in the friabilator, which was then 
operated for 100 revolutions at 25 rpm. The tablets were reweighed 
(W final) and the percentage friability was calculated for each batch 
by using the following formula. 
 
Weight variation test  
The 20 tablets OF 5-FU were selected at random from the lot, 
weighed individually and the average weight was determined. The 
percent deviation of each tablet weight against the average weight 
was calculated as per the official method [30]. 
Drug content uniformity 
The tablets of each 5-FU formulation were weighed and powdered. 
The quantity of powder equivalent to 500 mg of 5-FU was 
transferred into 100 ml volumetric flask and extracted with (pH-7.4) 
phosphate buffer and kept aside for 2 h. Then the solution was 
filtered and absorbance was measured by using Double Beam UV-Vis 
spectrophotometer (Shimadzu-1700, JAPAN) at 267 nm after 
suitable dilution [10]. 
Evaluation of oxaliplatin microspheres 
Surface morphology and particle size analysis of microspheres 
The scanning electron microscope (SEM) was adopted to analyze the 
size and surface morphology of the OX microspheres. The 
microspheres were set up on stubs with the help of a two-sided 
adhesive strip and placed on a respective slot. Then they looked 
under SEM (JOEL, JSM-5600 LV, JAPAN) to find the size and surface 
characteristics of OX microspheres [31]. 
Percentage yield of microspheres 
The prepared OX microspheres were collected, dried and further 
weighed. The obtained weight was then divided by the whole 
quantities of the OX and the excipients that were incorporated into 
the formulation of OX microspheres [32, 33]. 
 
Percentage drug entrapment efficiency of microspheres 
The evaluation of drug residence inside microspheres was carried 
out by an indirect method in which the aliquots were taken after 
crushing and filtering microspheres to remove broken beads and 
thereon were assayed spectrophotometrically at 240 wavelengths. 
The amount of OX entrapped was calculated from the difference 
between the whole quantity of OX involved in the formulation and 
the quantity of the OX traced in the filtered solution to that of the 
whole quantity of OX added [34]. 
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Fourier-transform infrared spectroscopy (FTIR) 
The compatibility of 5-FU and OX with adopted polymers was 
analyzed by using FT-IR in which the spectra for pure drug, physical 
mixture of polymers, 5-FU tablets, and OX loaded microspheres 
were recorded in a Fourier-Transform Infrared Spectrophotometer 
(PERKIN ELMER, USA) in the scanning range of 4000-400 cm-1 with 
the help of potassium bromide pellets. 
Differential scanning calorimetry (DSC) 
The thermal behaviors of 5-FU, OX, physical mixture of polymers, 5-
FU tablets, and OX loaded microspheres were examined with an 
automatic thermal analyzer system (DSC 60, SHIMADZU, JAPAN) 
using TDS tread line software. In this study, sealed aluminum-lead 
pans were adopted for all the samples and were run over a 
temperature range from 30 to 450 °C at a heating rate of 10 °C/min 
under an inert environment flushed with nitrogen at a rate of 20 
ml/min. 
In vitro dissolution study for 5-FU tablets under the simulated 
gastric and intestinal condition 
In vitro drug release study was carried out using a type 2 dissolution 
apparatus. To study the comparative release of 5-FU under different 
pH conditions, the experiment was performed in a variety of 
medium such as an acidic buffer (pH 2.0) for 2 h to simulate fasted 
stomach, phosphate buffer (PO4) (pH 4.5) to simulate duodenum, 
PO4 buffer (pH 6.8) to simulate mid jejunum and PO4 buffer (pH 7.4) 
to simulate ileo-colon conditions for almost 24 h. Samples (10 ml 
aliquots) were withdrawn at particular time intervals for 24 h and 
were centrifuged at 1500 rpm for 10 min. The amount of drug was 
quantified spectrophotometrically (UV 1700, SHIMADZU, JAPAN) at 
266 nm for 5-FU release. All dissolution tests were run in n=4 and 
the results were plotted as the percentage cumulative drug content 
released into dissolution medium versus time [35]. 
In vitro dissolution study for OX microspheres under the 
simulated gastric and intestinal condition 
The in vitro release of drug was conducted using USP type 1 
dissolution apparatus to accurately find the OX release. The different 
dissolution fluids of different pH values were adopted in this study. 
In 1st hour simulated gastric fluid of pH 1.2 was used, during the 
2ndhour mixture of simulated gastric and intestinal fluid of pH 4.5, 
further in 4-5th hour simulated intestinal fluid of pH 7.5 and finally in 
6-8th hour simulated colonic fluid of pH 7.0. In vitro release of drug 
from microspheres into 900 ml of simulated dissolution medium at 
37±1 °C with stirring under perfect sink conditions, further 
dissolution fluids were changed timely. Samples (10 ml aliquots) 
were withdrawn at a specified time and replaced with the same 
volume of fresh simulated fluid, and the amount of drug present was 
analyzed spectrophotometrically (UV 1700, Shimadzu, JAPAN) at 
240 nm for OX release. All dissolution tests were run in n=4 and the 
results were plotted as the percentage cumulative drug content 
released into dissolution medium versus time [36]. 
Ex vivo drug release study using rat caecal content 
The everted colon method was used to perform ex vivo studies. An 
intestinal segment of the rat was isolated, the colon part was everted 
and tied at one end. Further, into the sac-like everted colon, 7.4 
phosphate buffer, 5-FU tablets, and OX microspheres were added, 
which acts as a donor compartment. This everted colon was placed 
inside a beaker containing 7.4 phosphate buffers that act as a 
receptor compartment. Under aeration, the study was carried out for 
20 h. At 37 °C, samples were withdrawn at a 1 h time interval and 
were analyzed for the amount of drug released. All dissolution tests 
were run in n=4 and the results were plotted as the percentage 
cumulative drug content released into dissolution medium versus 
time [34]. 
RESULTS AND DISCUSSION 
Pre-compression parameters of 5-FU tablets 
The granules were evaluated for angle of repose, compressibility 
index, and hausner’s ratio and the obtained results were listed in 
table 4 and 5. The angle of repose less than 30 degree indicates good 
flow properties. The carr’s index of granules shown in table 4 and 5 
was obtained between 5-15%, that comes under an excellent 
category [37]. Thus the pre-compression properties of granules 
exhibited good results. 
 
Table 4: Pre-compression parameters of granule coated formulations 
Formulation code Angle of repose (θ) Bulk density (g/ml) Tapped density (g/ml) Carr’s index (%) Hausner’s ratio 
A1G 27.68±4.8 0.484±0.09 0.515±0.02 6±0.7 1.06±0.01 
A2G 27.35±3.9 0.490±0.04 0.524±0.04 6.4±0.9 1.06±0.01 
A3G 27.24±4.4 0.502±0.07 0.537±0.01 6.5±0.9 1.06±0.03 
A4G 27.21±2.8 0.513±0.07 0.540±0.07 5.4±0.1 1.05±0.01 
A5G 27.09±2.1 0.520±0.08 0.555±0.08 6.3±0.8 1.06±0.02 
A6G 27.22±3.6 0.525±0.04 0.560±0.07 6.3±0.4 1.06±0.01 
A7G 27.88±4.2 0.532±0.07 0.566±0.07 6.1±0.2 1.06±0.02 
A8G 28.89±2.1 0.533±0.07 0.574±0.08 7.1±1.1 1.07±0.01 
 *All values are expressed as mean±SD, (n=3). 
 
Table 5: Pre-compression parameters of tablet coated formulations 
Formulation code Angle of repose (θ) Bulk density (g/ml) Tapped density (g/ml) Carr’s index (%) Hausner’s ratio 
A1T 26.32±3.1 0.452±0.07 0.485±0.02 6.8±0.3 1.06±0.01 
A2T 25.83±6.1 0.459±0.04 0.497±0.02 7.6±0.9 1.07±0.01 
A3T 25.71±2.2 0.467±0.02 0.501±0.03 6.7±0.6 1.06±0.01 
A4T 25.68±1.7 0.484±0.02 0.515±0.07 6.01±0.2 1.06±0.03 
A5T 27.35±2.9 0.490±0.03 0.524±0.04 6.4±0.4 1.06±0.02 
A6T 27.24±3.3 0.502±0.04 0.537±0.02 6.5±0.7 1.06±0.01 
A7T 27.21±4.8 0.513±0.04 0.540±0.08 5.4±0.4 1.05±0.01 
A8T 27.09±2.6 0.520±0.04 0.555±0.04 6.3±0.3 1.06±0.01 
A9T 27.22±2.4 0.525±0.07 0.560±0.04 6.25±0.9 1.06±0.01 
A10T 26.88±1.2 0.532±0.07 0.566±0.07 6±0.4 1.06±0.03 
A11T 25.89±1.7 0.533±0.06 0.574±0.04 7.1±1.1 1.07±0.01 
A12T 25.98±3.2 0.546±0.04 0.582±0.04 6.1±0.8 1.06±0.01 
A13T 25.66±3.9 0.554±0.04 0.588±0.09 5.7±0.4 1.05±0.02 
A14T 25.75±1.9 0.566±0.04 0.602±0.02 5.5±0.2 1.05±0.01 
*All values are expressed as mean±SD, (n=3). 
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Post-compression parameters of 5-FU tablets 
The compressed 5-FU tablets were evaluated for hardness, friability, 
weight variation and drug content uniformity. The hardness of all 
compressed 5-FU tablets was in the range of 8.1 to 9.1 kg/cm2. The 
prepared 5-FU tablets were shown decent variability in weight under 
5% (w/w) and also shown good friability ranging between 0.11 to 0.2%, 
which is in prescribed limits [38]. Further, the 5-FU tablets were shown 
acceptable variation in weight and excellent uniformity in drug content 
of 265±40 mg and 97%, respectively as shown in the table 6 and 7. 
 
Table 6: Post-compression parameters of granule coated formulations 
Formulation code Average weight of tablet 
(mg) 
Weight variation (%) Hardness (kg/cm2) Friability (%) Drug content (%) 
A1G 255±21 2±1.6 8.6±2.6 0.13±0.01 99±2.1 
A2G 275±37 1.7±0.9 8.2±3.1 0.20±0.04 97.8±1.7 
A3G 257±29 1.1±1.2 8.1±1.2 0.17±0.03 98.8±1.4 
A4G 275±23 1.7±0.4 8.7±1.8 0.11±0.01 98.4±1.3 
A5G 255±27 2±0.4 8.6±2.7 0.13±0.04 99±1.3 
A6G 275±33 1.7±0.7 8.2±0.8 0.20±0.06 97.8±2.6 
A7G 305±39 1.6±0.1 8.8±0.9 0.16±0.02 98.2±2.2 
A8G 320±38 3±1.2 8.1±0.4 0.15±0.01 97.4±4.1 
*All values are expressed as mean±SD, (n=3) 
 
Table 7: Post-compression parameters of tablet coated formulations 
Formulation 
code 








Drug content (%) 
A1T 275±22 1.7±0.5 8.8±0.9 0.15±0.03 99.2±4.2 
A2T 300±31 1.6±0.7 8.4±1.6 0.20±0.01 97.8±2.7 
A3T 270±14 3.5±0.3 8.3±2.2 0.19±0.02 98.8±3.3 
A4T 300±29 1.6±0.9 8.4±1.4 0.13±0.01 98.4±6.6 
A5T 285±17 3.3±0.7 8.7±1.2 0.15±0.02 98.8±1.2 
A6T 310±40 3.2±1.2 9.1±0.8 0.20±0.01 97.8±7.1 
A7T 265±19 1.8±0.2 9.3±2.1 0.16±0.02 98.2±4.6 
A8T 295±35 1.6±0.7 8.2±0.6 0.17±0.05 97.4±3.7 
A9T 310±22 3.2±1.6 8.4±1.3 0.15±0.04 98.9±3.3 
A10T 340±39 2.9±0.9 8.7±1.8 0.20±0.01 97.8±3.8 
A11T 250±14 3.8±1.4 8.9±1.1 0.19±0.03 98.8±5.7 
A12T 245±29 2±0.4 8.8±1.9 0.13±0.02 98.4±2.4 
A13T 230±11 4.3±1.3 8.4±0.6 0.15±0.03 99±3 
A14T 220±16 4.5±1.7 8.6±1.1 0.20±0.02 98.8±4.4 
*All values are expressed as mean±SD, (n=3). 
 
Surface morphology and particle size analysis of microspheres 
The surface morphology of the microspheres was demonstrated 
from SEM micrographs in fig. 1. It was found that prepared OX 
microspheres were smaller in size and more uniform in shape. The 
surface morphology of microspheres showed fuller structure with 
fewer surface wrinkles; according to the SEM observation, the 
alginate and chitosan were formed a successful matrix by cross-
linking with ca+2 and zn+2. The sizes of the OX microspheres were 
ranged from 22-27 µm. 
 
 
Fig. 1: SEM observation of OX microspheres 
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Percentage yield and entrapment efficiency of microspheres 
OX microspheres were formulated by iontropic gelation technique 
and the percentage yield of the entire microsphere formulations 
were said to be in the range of 42.4-68.5% whose polymer 
concentration varied from low to high. The practical yield mainly 
depends on the concentration of polymer added into the 
formulation, as the concentration of polymer increases, the 
percentage yield will also be greater. The maximum yield obtained is 
68.5% for formulation A8M. 
The entrapment efficiency of the prepared microsphere was ranged 
from 58.3-74.4% depending upon varied polymer concentration. The 
percent entrapment efficiency increases due to elevated concentration 
of polymer up to a certain level; further greater polymer concentration 
results in decline of percent entrapment efficiency as seen in A4M and 
A8M. This shows that, greater the concentration of polymers than 
certain limit, bulkier the microspheres resulting in less area present 
for encapsulation of drug. The formulation A7M showed maximum 
entrapment efficiency of 74.4%. The detailed values for each 
preparation of OX microspheres were shown in table 8. 
 
Table 8: Percentage yield and encapsulation efficiency of microspheres 
Formulation code Percentage yield Entrapment efficiency 
A1M 42.42±0.12 73.2±0.34 
A2M 43.47±0.78 58.3±0.56 
A3M 55.93±0.91 67.8±0.23 
A4M 57.97±0.67 59.2±0.45 
A5M 43.75±0.89 62±0.12 
A6M 35.5±0.56 68.9±0.34 
A7M 55.17±0.78 74.4±0.91 
A8M 68.57±0.23 64.6±0.45 
A9M 42.96±0.89 69.6±0.67 
A10M 44.61±0.12 71.8±0.34 
A11M 50±0.78 66.93±0.56 
A12M 43.75±0.91 65.7±0.23 
A13M 52.8±0.67 71.43±0.45 
A14M 59.52±0.89 65.6±0.12 
*All values are expressed as mean±SD, (n=3). 
 
Fourier-transform infrared spectroscopy (FTIR) 
The FT-IR spectra of 5-FU, 5-FU tablet, physical mixture of tablet 
excipients, OX, OX microsphere and physical mixture of microsphere 
excipients are shown in fig. 1. N-H stretching vibrations at 3257 cm-
1, 3245 cm-1, C-H stretching vibrations at 3062 cm-1,3026 cm-1,-C-H2 
asymmetric and symmetric stretching vibrations at 2933 cm-1, 2827 
cm-1, and 2947 cm-1, 2896 cm-1,–C=C stretching vibrations at 1645 
cm-1, 1641 cm-1, N-H in plane bending vibrations at 1510 cm-1, 1411 
cm-1, Ring stretching vibrations at 1247 cm-1, 1245 cm-1, C-F 
stretching vibrations at 1224 cm-1, 1220 cm-1, N-H and C-H wagging 
vibrations at 933 cm-1, 995 cm-1C-F stretching vibrations at 813 cm-1, 
817 cm-1, pyrimidine ring vibrations at 754 cm-1, 752 cm-1 were 
observed for 5-FU and 5-FU tablet of A14T respectively. 
For the FT-IR spectrum of OX and OX microspheres of A14M, the 
peaks at 3264 cm-1, 3263 cm-1shows NH stretch, 3508 cm-1, 3514 
cm-1 for C-N stretch C=O stretch was observed at 1706 cm-1, 1645 
cm-1, and the peak at 811 cm-1,815 cm-1shows N-H bending 
respectively. 
The FT-IR spectrum of chitosan peaks at 2920 cm-1, 2950 cm-1for C-H 
stretching, the absorption band of carbonyl stretching of secondary 
amide at 1662 cm-1, 1667 cm-1, the bridge oxygen stretching bands at 
1068 cm-1 and 1039 cm-1, 1078 cm-1 and 1029 cm-1for 5-FU excipients 
and microsphere excipients respectively. Sodium alginate showed the 
distinctive peaks as a carbonyl, it depicted strong absorption bands at 
1602 cm-1, 1380 cm-1 due to carboxyl anions. The presence of sharp peak 
in fig. 2(b) and 2(c) at around 3500-3000 cm-1 indicates no physical 
interaction between chitosan and alginate, moreover, the distinct peaks 
for sodium alginate were present indicates no interaction between the 
excipients and the peaks of 5-FU were clearly shown that there was no 
apparent interaction between 5-FU and polymersas shown in fig. 2(b). 
The hydrogen bonding between alginate and chitosan were indicated by 
the broad peaks present in the range of 3500-3000 cm-1. Though OX 
shows C=O stretching vibrations at 1783 cm-1, sodium alginate is having 
a characteristic asymmetric stretching vibrations due to carboxyl anions 
at 1662 cm-1 and chitosan is having an absorption band of carbonyl 
stretching of secondary amide at 1598 cm-1 respectively in fig. 2(e), but 
the OX microparticles showed a peak at 1645 cm-1 in fig. 2(d) indicating 
the entrapment of OX into the ionic complex. 
 
 
Fig. 2(a): FT-IR of 5-FU 
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Fig. 2(b): FT-IR of 5-FU tablet (A14T) 
 
 
Fig. 2(c): FT-IR of the physical mixture of 5-FU tablet excipients 
 
 
Fig. 2(d): FT-IR of OX microspheres (A14M) 
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Fig. 2(e): FT-IR of the physical mixture of microsphere excipients 
 
Differential scanning calorimetry (DSC) 
The DSC is most crucial during the determination of the thermal 
behavior of formulation excipients that provides both quantitative 
and qualitative details about the state of the drug present inside the 
formulation. If a drug is dispersed in the solid-solution state or 
molecular dispersion in the polymeric system, there will not be any 
endotherm detected. In the present study DSC thermograms of pure 
5-FU, 5-FU tablet of A14T, physical mixture of tablet excipients, pure 
OX, OX microspheres of A14M, and physical mixture of microsphere 
excipients were taken. 
An exothermic peak correlate with 5-FU was found to be present at 
287.02 °C as shown in fig. 3(a). The exothermic peak correlate with a 
melting point of 5-FU in the sample of A14T shifted slightly to the 
277.1 °C, that may happened because of bound water presence in 
the sodium alginate and the DSC results indicate the non-existence 
of possible interactions between 5-FU and sodium alginate and 
other excipients as shown in fig. 3(b). 
Melting endotherms of pure OX, physical mixture of excipients and 
oxaliplatin microspheres of A14M showed the presence of 
endothermic peaks at 287.58 °C, 248.92 °C, and 271.68 °C 
respectively depicted in fig. 3(d) and (e). Besides, considerable 
exothermic peaks were observed at 104.86 °C, 99.5 °C for 
microsphere excipients and OX microspheres, respectively, 
stipulating the crystalline characteristic of the polymers. However, 
the absence of the OX characteristic peak in OX microspheres, which 
showed a negligible broad peak at 271.68 °C, indicating that the OX 
was molecularly dispersed inside microspheres. Due to the presence 
of polymers in microsphere formulation, the peak sharpness and 
height reduction is observed. 
 
 
Fig. 3(a): DSC of 5-FU 
 
In vitro dissolution study for granules coated 5-FU, tablet 
coated 5-FU and oxaliplatin microspheres 
To study the effect of various polymers that were used, initially, the 
dissolution was carried out for 10 h for A1T-A6T and A1G-A4G. 
Tablet coatings released a lesser amount of 5-FU for 10 h in 7.4 
phosphate buffer. But granule coating exhibited promising drug 
release within 10 h in 7.4 phosphate buffers to proceed further for 
24 h study. Guar gum was used in A3T, A4T, A3G, A4G, formulations 
instead of alginate. Significant differences in the release profiles 
weren't observed between alginate and guar gum and hence further 
studies were planned with alginate, owing to the fact that guar gum 
was used in a lot many formulations for preparing 5-FU tablets 
previously. The release profiles changed contrastingly in 24 h study 
with a coated capsule. The very low release profiles of granule 
coating ruled out the chances of using them for further study. On the 
other hand, though the tablet coatings too don't have a better 
release, they have better release enough to continue with them for 
further. The studies show a direct relationship between the amount 
of alginate added into the formulation and the amount of eudragit 
RSPO coated on to the tablet to that of the drug release. The 
reduction in the coating concentration from 50 mg to 20 mg and 
alginate from 100 mg to 50 mg in A7T released just 40.9% in 24 h. 
By gradual reduction in the 50 mg of alginate taken in A7T and 
keeping 20 mg eudragit RSPO coating constant four formulations 
were prepared to have 40, 30, 20 and 10 mg of alginate. As the 
concentration of alginate decreased, the cumulative release of 5-FU 
was increased to 49.3%, 59.1%, 76.4%, and 90.3% respectively at 
the end of 24 h. The detailed percentage drug release for tablet 
coated 5-FU, granule coated 5-FU were shown in fig. 4. 
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Fig. 3(b): DSC of 5-FU tablet (A14T) 
 
 
Fig. 3(c): DSC of the physical mixture of tablet excipients 
 
 
Fig. 3(d): DSC of OX microspheres (A14M) 
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Fig. 3(e): DSC of the physical mixture of microsphere excipients 
 
 
Fig. 4(a): Dissolution profile of A1T-A6T, *results are expressed as mean±SD, (n=4) 
 
 
Fig. 4(b): Dissolution profile of A1G-A4G, *results are expressed as mean±SD, (n=4) 
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Fig. 4(c): Dissolution profile of A5G-A8G, *results are expressed as mean±SD, (n=4) 
 
 
Fig. 4(d): Dissolution profile of A7T-A14T, *results are expressed as mean±SD, (n=4) 
 
 
Fig. 5(a): Dissolution profile of A1M-A8M, *results are expressed as mean±SD, (n=4) 
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Fig. 5(b): Dissolution profile of A9M-A14M, *results are expressed as mean±SD, (n=4) 
 
The dose of OX is on the lower end compared to that of 5-FU and with 
that small dose, microspheres were comfortably prepared. Based on the 
solubility profile of oxaliplatin, the ionotropic gelation method was 
adopted as the method of choice for the formulation of oxaliplatin 
microspheres and finally prepared microspheres were filled into a 
capsule. At the end of the 5th hour, not more than 5% of 5-FU was 
released. Again alginate slows down the drug release noticeably from OX 
microspheres. Since OX microspheres had to release the drug completely 
in 10 h, the weight of alginate was reduced in the microspheres. Here in 
microspheres, the alginate concentration reduction isn't that easy as 
compared to a 5-FU tablet. A1M and A7M were selected to proceed 
further by reducing the alginate concentration, here the amount of 
alginate was reduced concerning the other polymers. Zinc sulfate helped 
in sustaining the drug release but it was not used in other formulations. 
Eudragit S-100 coat on capsules was reduced to 8% and carried out 
further formulations concerning A1M and A7M. The reason behind 
choosing these two formulations is their high encapsulation efficiencies 
at 73.2% and 74.4% respectively. The absence of zinc sulfate didn't show 
any effect on the encapsulation efficiencies and by carefully controlling 
the amount of alginate and coating on to the capsules the cumulative 
release for A13M and A14M were recorded as 62.31% and 79.63% 
respectively. The detailed percentage drug release for OX microspheres 
were shown in fig. 5. 
Ex vivo drug release study using rat caecal content 
The ex vivo studies were carried out in an everted colon technique 
in the presence of caecal content. Since the A14M and A14T 
formulations exhibited a higher rate of drug release we are taking 
them as optimized formulations to carryout ex vivo studies. The pH-
sensitive polymer-coated capsule was not used in this study along 
with microspheres and tablets due to the test directly carried out in 
the simulated colonic condition. The results were found to be 76% 
and 78% of drug released for OX microspheres (A14M) and 5-FU 
tablets (A14T) respectively at specific time points as shown in fig. 6. 
 
 
Fig. 6: Ex vivo drug release study of OX microspheres (A14M) and 5-FU tablet (A14T), *results are expressed as mean±SD, (n=4) 
 
CONCLUSION 
The two different formulations were designed selectively to deliver 
5-FU and OX to the colon region in synchronization with circadian 
timing system (Chronotherapy). Both the tablet and microsphere 
formulations were found to be successful in case of controlled drug 
release. Among all the other formulations, A14T and A14M were 
showed maximum drug release at 24 h and 9 h respectively. This 
demonstrated that optimization of polymer ratio and concentrations 
of coating solution are very important to achieve delayed drug 
release. Wherefore the current study believed that 5-FU tablets and 
OX microspheres prepared by using varied concentration of 
polymers that were further filled into capsules and coated with pH-
sensitive polymer eudragit S-100 can be efficiently used to control 
the rate of drug release to the colon in synchronization with 
circadian timing system same as chronomodulated chemotherapy 
treatment given through intravenous route in the belief of improved 
therapeutic efficacy, tolerability and overall survival rate of cancer 
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patients. Thus it can be a very good alternative for intravenous route 
based chronomodulated chemotherapy. 
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